Heart failure and Alzheimer′s disease

Journal of Internal Medicine

Volumn 277, Issue 4, 2015, Pages 406-425

  Cermakova, P ^a,b   Eriksdotter, M ^a,c   Lund, L H ^a,c   Winblad, B ^a,c   Religa, P ^a   Religa, D ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer s disease; Dementia; Heart failure; Neurocardiology; Neurovascular unit

Indexed keywords

AMYLOID BETA PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; NOOTROPIC AGENT; TAU PROTEIN;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN PERFUSION; COGNITION; CORONARY ARTERY DISEASE; DELIRIUM; DEMENTIA; DEMYELINATION; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; SLEEP DISORDERED BREATHING; VALVULAR HEART DISEASE; ANIMAL; ATRIAL FIBRILLATION; BRAIN CIRCULATION; DISEASE MODEL; HEART STROKE VOLUME; HUMAN; HYPERTENSION; INTRACRANIAL ARTERIOSCLEROSIS; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; RISK FACTOR; SLEEP APNEA SYNDROMES;

ALZHEIMER DISEASE; ANIMALS; ATRIAL FIBRILLATION; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; HYPERTENSION; INTRACRANIAL ARTERIOSCLEROSIS; MYOCARDIAL INFARCTION; RISK FACTORS; SLEEP APNEA SYNDROMES; STROKE VOLUME;

EID: 84925298330     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12287     Document Type: Review

References (241)

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63-75.e2.
2. Wimo A, Jonsson L, Bond J, Prince M, Winblad B., Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013; 9: 1-11.e3.
3. Wallin K, Bostrom G, Kivipelto M, Gustafson Y. Risk factors for incident dementia in the very old. Int Psychogeriatr 2013; 25: 1135-43.
4. Kivipelto M, Helkala EL, Laakso MP et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-51.
5. Kivipelto M, Ngandu T, Fratiglioni L et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62: 1556-60.
6. Huang W, Qiu C, von Strauss E, Winblad B, Fratiglioni L. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol 2004; 61: 1930-4.
7. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med 2006; 166: 1003-8.
8. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-220.
9. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3: 315-22.
10. Nieminen MS, Bohm M, Cowie MR et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.
11. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-18.
12. Chhatre S, Weiner MG, Jayadevappa R, Johnson JC. Incremental burden of congestive heart failure among elderly with Alzheimer's. Aging Ment Health 2009; 13: 628-34.
13. Vogels RL, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail 2007; 9: 440-9.
14. Pressler SJ, Kim J, Riley P, Ronis DL, Gradus-Pizlo I. Memory dysfunction, psychomotor slowing, and decreased executive function predict mortality in patients with heart failure and low ejection fraction. J Cardiac Fail 2010; 16: 750-60.
15. Roher AE, Debbins JP, Malek-Ahmadi M et al. Cerebral blood flow in Alzheimer's disease. Vasc Health Risk Manag 2012; 8: 599-611.
16. Hoth KF, Poppas A, Moser DJ, Paul RH, Cohen RA. Cardiac dysfunction and cognition in older adults with heart failure. Cogn Behav Neurol 2008; 21: 65-72.
17. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.
18. de la Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry and Neurol 2012; 2012: 367516.
19. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-51.
20. Khachaturian AS, Zandi PP, Lyketsos CG et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006; 63: 686-92.
21. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3: 186-91.
22. Rocca WA, Petersen RC, Knopman DS et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement 2011; 7: 80-93.
23. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining?: trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 2012; 78: 1456-63.
24. Qiu C, von Strauss E, Backman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013; 80: 1888-94.
25. Christensen K, Thinggaard M, Oksuzyan A et al. Physical and cognitive functioning of people older than 90 years: a comparison of two Danish cohorts born 10 years apart. Lancet 2013; 382: 1507-13.
26. Matthews FE, Arthur A, Barnes LE et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013; 382: 1405-12.
27. Gustafson Y. Postoperative delirium-a challenge for the orthopedic team. Acta Orthop Scand 2004; 75: 375-7.
28. Eriksson I, Gustafson Y, Fagerstrom L, Olofsson B. Urinary tract infection in very old women is associated with delirium. Int Psychogeriatr 2011; 23: 496-502.
29. Laurila JV, Laakkonen ML, Tilvis RS, Pitkala KH. Predisposing and precipitating factors for delirium in a frail geriatric population. J Psychosom Res 2008; 65: 249-54.
30. Kiely DK, Marcantonio ER, Inouye SK et al. Persistent delirium predicts greater mortality. J Am Geriatr Soc 2009; 57: 55-61.
31. Mathillas J, Olofsson B, Lovheim H, Gustafson Y. Thirty-day prevalence of delirium among very old people: a population-based study of very old people living at home and in institutions. Arch Gerontol Geriatr 2013; 57: 298-304.
32. Krogseth M, Wyller TB, Engedal K, Juliebo V. Delirium is an important predictor of incident dementia among elderly hip fracture patients. Dement Geriatr Cogn Disord 2011; 31: 63-70.
33. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9.
34. Donal E, Lund LH, Linde C et al. Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. Eur J Heart Fail 2009; 11: 198-204.
35. Donal E, Thebault C, Lund LH et al. Heart failure with a preserved ejection fraction additive value of an exercise stress echocardiography. Eur Heart J Cardiovasc Imaging 2012; 13: 656-65.
36. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol 2012; 60: 2349-56.
37. Cardiogenic Dementia. Lancet 1977; 1: 27-8.
38. Debette S, Bauters C, Leys D, Lamblin N, Pasquier F, de Groote P. Prevalence and determinants of cognitive impairment in chronic heart failure patients. Congest Heart Fail 2007; 13: 205-8.
39. Cohen MB, Mather PJ. A review of the association between congestive heart failure and cognitive impairment. Am J Geriatr Cardiol 2007; 16: 171-4.
40. Jefferson AL. Cardiac output as a potential risk factor for abnormal brain aging. J Alzheimers Dis 2010; 20: 813-21.
41. Jefferson AL, Himali JJ, Au R et al. Relation of left ventricular ejection fraction to cognitive aging (from the Framingham Heart Study). Am J Cardiol 2011; 108: 1346-51.
42. Zuccala G, Cattel C, Manes-Gravina E, Di Niro MG, Cocchi A, Bernabei R. Left ventricular dysfunction: a clue to cognitive impairment in older patients with heart failure. J Neurol Neurosurg Psychiatry 1997; 63: 509-12.
43. Putzke JD, Williams MA, Daniel JF, Foley BA, Kirklin JK, Boll TJ. Neuropsychological functioning among heart transplant candidates: a case control study. J Clin Exp Neuropsychol 2000; 22: 95-103.
44. Deshields TL, McDonough EM, Mannen RK, Miller LW. Psychological and cognitive status before and after heart transplantation. Gen Hosp Psychiatry 1996; 18: 62S-9S.
45. Roman DD, Kubo SH, Ormaza S, Francis GS, Bank AJ, Shumway SJ. Memory improvement following cardiac transplantation. J Clin Exp Neuropsychol 1997; 19: 692-7.
46. Dodson JA, Truong TT, Towle VR, Kerins G, Chaudhry SI. Cognitive impairment in older adults with heart failure: prevalence, documentation, and impact on outcomes. Am J Med 2013; 126: 120-6.
47. Uthamalingam S, Gurm GS, Daley M, Flynn J, Capodilupo R. Usefulness of acute delirium as a predictor of adverse outcomes in patients >65 years of age with acute decompensated heart failure. Am J Cardiol 2011; 108: 402-8.
48. Hjelm C, Brostrom A, Dahl A, Johansson B, Fredrikson M, Stromberg A. Factors associated with increased risk for dementia in individuals age 80 years or older with congestive heart failure. J Cardiovasc Nurs 2013; 29: 82-90.
49. Roman GC. Vascular dementia prevention: a risk factor analysis. Cerebrovasc Dis 2005; 20(Suppl 2): 91-100.
50. Vogels RL, van der Flier WM, van Harten B et al. Brain magnetic resonance imaging abnormalities in patients with heart failure. Eur J Heart Fail 2007; 9: 1003-9.
51. Kumar R, Woo MA, Macey PM, Fonarow GC, Hamilton MA, Harper RM. Brain axonal and myelin evaluation in heart failure. J Neurol Sci 2011; 307: 106-13.
52. Serber SL, Kumar R, Woo MA, Macey PM, Fonarow GC, Harper RM. Cognitive test performance and brain pathology. Nurs Res 2008; 57: 75-83.
53. Prins ND, van der Flier WM, Brashear HR et al. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. J Alzheimers Dis 2013; 36: 79-85.
54. Jefferson AL, Himali JJ, Beiser AS et al. Cardiac index is associated with brain aging: the Framingham Heart Study. Circulation 2010; 122: 690-7.
55. Vasudev A, Saxby BK, O'Brien JT et al. Relationship between cognition, magnetic resonance white matter hyperintensities, and cardiovascular autonomic changes in late-life depression. Am J Geriatr Psychiatry 2012; 20: 691-9.
56. Farid K, Petras S, Ducasse V et al. Brain perfusion SPECT imaging and acetazolamide challenge in vascular cognitive impairment. Nucl Med Commun 2012; 33: 571-80.
57. Bronge L, Wahlund LO. White matter changes in dementia: does radiology matter? Br J Radiol 2007; 80 Spec No 2: S115-20.
58. Scheibel AB, Duong TH, Jacobs R. Alzheimer's disease as a capillary dementia. Ann Med 1989; 21: 103-7.
59. Yoshikawa T, Murase K, Oku N et al. Heterogeneity of cerebral blood flow in Alzheimer disease and vascular dementia. AJNR Am J Neuroradiol 2003; 24: 1341-7.
60. Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol 2011; 37: 56-74.
61. Johnson NA, Jahng GH, Weiner MW et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005; 234: 851-9.
62. Mazza M, Marano G, Traversi G, Bria P, Mazza S. Primary cerebral blood flow deficiency and Alzheimer's disease: shadows and lights. J Alzheimers Dis 2011; 23: 375-89.
63. Ruitenberg A, den Heijer T, Bakker SL et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 2005; 57: 789-94.
64. Rombouts SA, Goekoop R, Stam CJ, Barkhof F, Scheltens P. Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. NeuroImage 2005; 26: 1078-85.
65. Hirao K, Ohnishi T, Hirata Y et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. NeuroImage 2005; 28: 1014-21.
66. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009; 118: 103-13.
67. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109: 813-36.
68. Choi BR, Kim JS, Yang YJ et al. Factors associated with decreased cerebral blood flow in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2006; 97: 1365-9.
69. Paulson OB, Jarden JO, Godtfredsen J, Vorstrup S. Cerebral blood flow in patients with congestive heart failure treated with captopril. Am J Med 1984; 76: 91-5.
70. Gruhn N, Larsen FS, Boesgaard S et al. Cerebral blood flow in patients with chronic heart failure before and after heart transplantation. Stroke 2001; 32: 2530-3.
71. Massaro AR, Dutra AP, Almeida DR, Diniz RV, Malheiros SM. Transcranial Doppler assessment of cerebral blood flow: effect of cardiac transplantation. Neurology 2006; 66: 124-6.
72. de la Torre JC. Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neuro-Degener Dis 2008; 5: 126-32.
73. Pirchl M, Humpel C. [Does acidosis in brain play a role in Alzheimer's disease?]. Neuropsychiatr 2009; 23: 187-92.
74. Ishizaki T, Erickson A, Kuric E et al. The asparaginyl endopeptidase legumain after experimental stroke. J Cereb Blood Flow Metab 2010; 30: 1756-66.
75. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 2005; 22: 1942-50.
76. Kolarova M, Garcia-Sierra F, Bartos A, Ricny J, Ripova D. Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis 2012; 2012: 731526.
77. Iqbal K, Gong CX, Liu F. Hyperphosphorylation-induced tau oligomers. Front Neurol 2013; 4: 112.
78. Velliquette RA, O'Connor T, Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 2005; 25: 10874-83.
79. Bailey TL, Rivara CB, Rocher AB, Hof PR. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 2004; 26: 573-8.
80. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-60.
81. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
82. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140: 918-34.
83. Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernandez J, Campos-Pena V. Inflammatory process in Alzheimer's Disease. Front Integr Neurosci 2013; 7: 59.
84. Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 2008; 12: 762-80.
85. Harry GJ. Microglia during development and aging. Pharmacol Ther 2013; 139: 313-26.
86. Bell RD, Winkler EA, Singh I et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012; 485: 512-6.
87. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008; 29: 367-74.
88. Armulik A, Genove G, Mae M et al. Pericytes regulate the blood-brain barrier. Nature 2010; 468: 557-61.
89. Ritz K, van Buchem MA, Daemen MJ. The heart-brain connection: mechanistic insights and models. Neth Heart J 2013; 21: 55-7.
90. Arai K, Lo EH. Astrocytes protect oligodendrocyte precursor cells via MEK/ERK and PI3K/Akt signaling. J Neurosci Res 2010; 88: 758-63.
91. Thal DR, Griffin WS, de Vos RA, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol 2008; 115: 599-609.
92. Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke 2004; 35: 2616-9.
93. Okamoto Y, Yamamoto T, Kalaria RN et al. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 2012; 123: 381-94.
94. White M, Ducharme A, Ibrahim R et al. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci 2006; 110: 483-9.
95. Religa P, Cao R, Religa D et al. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci Rep 2013; 3: 2053.
96. Grudzinska MK, Kurzejamska E, Bojakowski K et al. Monocyte chemoattractant protein 1-mediated migration of mesenchymal stem cells is a source of intimal hyperplasia. Arterioscler Thromb Vasc Biol 2013; 33: 1271-9.
97. Bink DI, Ritz K, Aronica E, van der Weerd L, Daemen MJ. Mouse models to study the effect of cardiovascular risk factors on brain structure and cognition. J Cereb Blood Flow Metab 2013; 33: 1666-84.
98. Shibata M, Ohtani R, Ihara M, Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke 2004; 35: 2598-603.
99. Fujita Y, Ihara M, Ushiki T et al. Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke 2010; 41: 2938-43.
100. Nishio K, Ihara M, Yamasaki N et al. A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke 2010; 41: 1278-84.
101. Coltman R, Spain A, Tsenkina Y et al. Selective white matter pathology induces a specific impairment in spatial working memory. Neurobiol Aging 2011; 32: 2324.e7-12.
102. Mrzilkova J, Zach P, Bartos A, Tintera J, Ripova D. Volumetric analysis of the pons, cerebellum and hippocampi in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 34: 224-34.
103. Zakzanis KK, Graham SJ, Campbell Z. A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile. Neuropsychol Rev 2003; 13: 1-18.
104. Nakamura A, Rokosh DG, Paccanaro M et al. LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. Am J Physiol Heart Circ Physiol 2001; 281: H1104-12.
105. Gentile MT, Poulet R, Di Pardo A et al. Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging 2009; 30: 222-8.
106. Kitaguchi H, Tomimoto H, Ihara M et al. Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Brain Res 2009; 1294: 202-10.
107. Pluta R. The role of apolipoprotein E in the deposition of beta-amyloid peptide during ischemia-reperfusion brain injury. A model of early Alzheimer's disease. Ann N Y Acad Sci 2000; 903: 324-34.
108. Alosco ML, Brickman AM, Spitznagel MB et al. The independent association of hypertension with cognitive function among older adults with heart failure. J Neurol Sci 2012; 323: 216-20.
109. Trojano L, Antonelli Incalzi R, Acanfora D et al. Cognitive impairment: a key feature of congestive heart failure in the elderly. J Neurol 2003; 250: 1456-63.
110. Goyal D, Macfadyen RJ, Watson RD, Lip GY. Ambulatory blood pressure monitoring in heart failure: a systematic review. Eur J Heart Fail 2005; 7: 149-56.
111. Mosterd A, Cost B, Hoes AW et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J 2001; 22: 1318-27.
112. Zuccala G, Onder G, Pedone C et al. Hypotension and cognitive impairment: selective association in patients with heart failure. Neurology 2001; 57: 1986-92.
113. den Abeelen AS, Lagro J, van Beek A, Claassen J. Impaired cerebral autoregulation and vasomotor reactivity in sporadic Alzheimer's in disease. Curr Alzheimer Res 2014; 11: 7.
114. Skoog I, Lernfelt B, Landahl S et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.
115. Qiu C, von Strauss E, Winblad B, Fratiglioni L. Decline in blood pressure over time and risk of dementia: a longitudinal study from the Kungsholmen project. Stroke 2004; 35: 1810-5.
116. Fitzgerald AA, Powers JD, Ho PM et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Cardiac Fail 2011; 17: 664-9.
117. Sabayan B, Wijsman LW, Foster-Dingley JC et al. Association of visit-to-visit variability in blood pressure with cognitive function in old age: prospective cohort study. BMJ 2013; 347: f4600.
118. Ruland S, Aiyagari V. Cerebral autoregulation and blood pressure lowering. Hypertension 2007; 49: 977-8.
119. Domanski MJ, Mitchell GF, Norman JE, Exner DV, Pitt B, Pfeffer MA. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33: 951-8.
120. Eklind-Cervenka M, Benson L, Dahlstrom U, Edner M, Rosenqvist M, Lund LH. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA 2011; 305: 175-82.
121. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 1972; 287: 781-7.
122. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274: 1846-51.
123. Igase M, Kohara K, Miki T. The Association between Hypertension and Dementia in the Elderly. Int J Hypertens 2012; 2012: 320648.
124. Applegate WB, Pressel S, Wittes J et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 1994; 154: 2154-60.
125. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.
126. Waldstein SR, Manuck SB, Ryan CM, Muldoon MF. Neuropsychological correlates of hypertension: review and methodologic considerations. Psychol Bull 1991; 110: 451-68.
127. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-71.
128. van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann Neurol 2007; 61: 403-10.
129. Roher AE, Tyas SL, Maarouf CL et al. Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Alzheimers Dement 2011; 7: 436-44.
130. Kalback W, Esh C, Castano EM et al. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res 2004; 26: 525-39.
131. Krishnaswamy G. The inflammation paradigm and coronary artery disease: what Celsus, Virchow and gene knock outs have taught us. Cardiovascu Hematol Disord Drug Targets 2010; 10: 246-56.
132. Kovacic JC, Castellano JM, Fuster V. The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease. Ann N Y Acad Sci 2012; 1254: 99-105.
133. Olazaran J, Ramos A, Boyano I et al. Pattern of and risk factors for brain microbleeds in neurodegenerative dementia. Am J Alzheimers Dis Other Demen 2014; 29: 263-9.
134. Webber BJ, Seguin PG, Burnett DG, Clark LL, Otto JL. Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011. JAMA 2012; 308: 2577-83.
135. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349-56.
136. Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-83.
137. Prince M, Cullen M, Mann A. Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC elderly hypertension trial. Neurology 1994; 44: 97-104.
138. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003; 163: 1524-8.
139. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002; 52: 168-74.
140. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-42.
141. Newman AB, Fitzpatrick AL, Lopez O et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 2005; 53: 1101-7.
142. Hofman A, Ott A, Breteler MM et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-4.
143. Yarchoan M, Xie SX, Kling MA et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 2012; 135: 3749-56.
144. Beach TG, Wilson JR, Sue LI et al. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol 2007; 113: 13-21.
145. Roher AE, Esh C, Kokjohn TA et al. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 2003; 23: 2055-62.
146. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005; 64: 494-500.
147. Kosunen O, Talasniemi S, Lehtovirta M et al. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke 1995; 26: 743-8.
148. Zheng L, Vinters HV, Mack WJ, Zarow C, Ellis WG, Chui HC. Cerebral atherosclerosis is associated with cystic infarcts and microinfarcts but not alzheimer pathologic changes. Stroke 2013; 44: 2835-41.
149. Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, Obrien RJ. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann Neurol 2010; 68: 231-40.
150. Wolf PA. Contributions of the Framingham Heart Study to stroke and dementia epidemiologic research at 60 years. Arch Neurol 2012; 69: 567-71.
151. Roberts RO, Knopman DS, Geda YE, Cha RH, Roger VL, Petersen RC. Coronary heart disease is associated with non-amnestic mild cognitive impairment. Neurobiol Aging 2010; 31: 1894-902.
152. Koschack J, Irle E. Small hippocampal size in cognitively normal subjects with coronary artery disease. Neurobiol Aging 2005; 26: 865-71.
153. Stellos K, Katsiki N, Tatsidou P, Bigalke B, Laske C. Association of platelet activation with vascular cognitive impairment: implications in dementia development? Curr Vasc Pharmacol 2012; 12: 152-4.
154. Graban A, Bednarska-Makaruk M, Bochynska A, Lipczynska-Lojkowska W, Ryglewicz D, Wehr H. Vascular and biochemical risk factors of vascular dementia after lacunar strokes (S-VaD) and after multiinfarcts in strategic areas (M-VaD). J Neurol Sci 2009; 283: 116-8.
155. Ikram MA, van Oijen M, de Jong FJ et al. Unrecognized myocardial infarction in relation to risk of dementia and cerebral small vessel disease. Stroke 2008; 39: 1421-6.
156. Aronson MK, Ooi WL, Morgenstern H et al. Women, myocardial infarction, and dementia in the very old. Neurology 1990; 40: 1102-6.
157. Petrovitch H, White L, Masaki KH et al. Influence of myocardial infarction, coronary artery bypass surgery, and stroke on cognitive impairment in late life. Am J Cardiol 1998; 81: 1017-21.
158. Bursi F, Rocca WA, Killian JM et al. Heart disease and dementia: a population-based study. Am J Epidemiol 2006; 163: 135-41.
159. Linssen GC, Rienstra M, Jaarsma T et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2011; 13: 1111-20.
160. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: VI102-10.
161. Donal E, Lund LH, Oger E et al. Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. Arch Cardiovasc Dis 2013; 107: 112-21.
162. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009; 119: 2516-25.
163. Knecht S, Oelschlager C, Duning T et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29: 2125-32.
164. Thacker EL, McKnight B, Psaty BM et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology 2013; 81: 119-25.
165. Elias MF, Sullivan LM, Elias PK et al. Atrial fibrillation is associated with lower cognitive performance in the Framingham offspring men. J Stroke Cerebrovasc Dis 2006; 15: 214-22.
166. Wozakowska-Kaplon B, Opolski G, Kosior D, Jaskulska-Niedziela E, Maroszynska-Dmoch E, Wlosowicz M. Cognitive disorders in elderly patients with permanent atrial fibrillation. Kardiol Pol 2009; 67: 487-93.
167. Dublin S, Anderson ML, Haneuse SJ et al. Atrial fibrillation and risk of dementia: a prospective cohort study. J Am Geriatr Soc 2011; 59: 1369-75.
168. Miyasaka Y, Barnes ME, Petersen RC et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J 2007; 28: 1962-7.
169. Cacciatore F, Testa G, Langellotto A et al. Role of ventricular rate response on dementia in cognitively impaired elderly subjects with atrial fibrillation: a 10-year study. Dement Geriatr Cogn Disord 2012; 34: 143-8.
170. Forti P, Maioli F, Pisacane N, Rietti E, Montesi F, Ravaglia G. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment (MCI). Arch Gerontol Geriatr 2007; 44(Suppl 1): 155-65.
171. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997; 28: 316-21.
172. Bunch TJ, Weiss JP, Crandall BG et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm 2010; 7: 433-7.
173. Marengoni A, Qiu C, Winblad B, Fratiglioni L. Atrial fibrillation, stroke and dementia in the very old: a population-based study. Neurobiol Aging 2011; 32: 1336-7.
174. Park H, Hildreth A, Thomson R, O'Connell J. Non-valvular atrial fibrillation and cognitive decline: a longitudinal cohort study. Age Ageing 2007; 36: 157-63.
175. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med 2013; 158: 338-46.
176. Lip GY, Piotrponikowski P, Andreotti F et al. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost 2012; 108: 1009-22.
177. Russell D. Cerebral microemboli and cognitive impairment. J Neurol Sci 2002; 203-204: 211-4.
178. Purandare N, Burns A, Daly KJ et al. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: case-control study. BMJ 2006; 332: 1119-24.
179. Muqtadar H, Testai FD, Gorelick PB. The dementia of cardiac disease. Curr Cardiol Rep 2012; 14: 732-40.
180. American College of Cardiology Foundation, American Heart Association, European Society of Cardiology, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013; 127: 1916-26.
181. Tavassoli N, Perrin A, Berard E, Gillette S, Vellas B, Rolland Y, the RFRG. Factors associated with undertreatment of atrial fibrillation in geriatric outpatients with Alzheimer disease. Am J Cardiovascu Drugs 2013; 13: 425-33.
182. Tulner LR, Van Campen JP, Kuper IM et al. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging 2010; 27: 39-50.
183. Rabah A, Wazni O. Atrial fibrillation in heart failure: catheter and surgical interventional therapies. Heart Fail Rev 2013; 19: 325-30.
184. de la Torre JC. How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res 2006; 28: 637-44.
185. Corder EH, Ervin JF, Lockhart E, Szymanski MH, Schmechel DE, Hulette CM. Cardiovascular damage in Alzheimer disease: autopsy findings from the Bryan ADRC. J Biomed Biotechnol 2005; 2005: 189-97.
186. Reitz C, Brickman AM, Luchsinger JA, Wu WE, Small SA, Tang MX. Frequency of subclinical heart disease in elderly persons with dementia. Am J Geriatr Cardiol 2007; 16: 183-8.
187. Belohlavek M, Jiamsripong P, Calleja AM et al. Patients with Alzheimer disease have altered transmitral flow: echocardiographic analysis of the vortex formation time. J Ultrasound Med 2009; 28: 1493-500.
188. Morgenthaler TI, Kagramanov V, Hanak V, Decker PA. Complex sleep apnea syndrome: is it a unique clinical syndrome? Sleep 2006; 29: 1203-9.
189. Janssens JP, Pautex S, Hilleret H, Michel JP. Sleep disordered breathing in the elderly. Aging 2000; 12: 417-29.
190. Shahar E, Whitney CW, Redline S et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25.
191. Bitter T, Faber L, Hering D, Langer C, Horstkotte D, Oldenburg O. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 2009; 11: 602-8.
192. Chan J, Sanderson J, Chan W et al. Prevalence of sleep-disordered breathing in diastolic heart failure. Chest 1997; 111: 1488-93.
193. Young T, Shahar E, Nieto FJ et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med 2002; 162: 893-900.
194. 2 and circulatory delay. Circulation 2001; 103: 238-43.
195. Mentz RJ, Fiuzat M. Sleep-disordered breathing in patients with heart failure. Heart Fail Clin 2014; 10: 243-50.
196. Ng AC, Freedman SB. Sleep disordered breathing in chronic heart failure. Heart Fail Rev 2009; 14: 89-99.
197. Javaheri S. A mechanism of central sleep apnea in patients with heart failure. N Engl J Med 1999; 341: 949-54.
198. Janssens JP, Pautex S, Hilleret H, Michel JP. [Respiratory sleep disorders in the elderly]. Rev Med Suisse Romande 2000; 120: 869-79.
199. Kinugawa K, Nguyen-Michel VH, Nguyen-Michel VH, Mariani J. [Obstructive sleep apnea syndrome: a cause of cognitive disorders in the elderly?]. La Revue de Medecine Interne/Fondee par la Societe Nationale Francaise de Medecine Interne 2014. [Epub ahead of print].
200. Dyken ME, Yamada T, Glenn CL, Berger HA. Obstructive sleep apnea associated with cerebral hypoxemia and death. Neurology 2004; 62: 491-3.
201. Daulatzai MA. Death by a thousand cuts in Alzheimer's disease: hypoxia-the prodrome. Neurotox Res 2013; 24: 216-43.
202. Daulatzai MA. Pathogenesis of cognitive dysfunction in patients with obstructive sleep apnea: a hypothesis with emphasis on the nucleus tractus solitarius. Sleep Disord 2012; 2012: 251096.
203. Cooke JR, Ayalon L, Palmer BW et al. Sustained use of CPAP slows deterioration of cognition, sleep, and mood in patients with Alzheimer's disease and obstructive sleep apnea: a preliminary study. J Clin Sleep Med 2009; 5: 305-9.
204. Ayalon L, Ancoli-Israel S, Stepnowsky C et al. Adherence to continuous positive airway pressure treatment in patients with Alzheimer's disease and obstructive sleep apnea. Am J Geriatr Psychiatry 2006; 14: 176-80.
205. Jonsson A, Edner M, Alehagen U, Dahlstrom U. Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 2010; 12: 25-31.
206. Blood Pressure Lowering Treatment, Trialists C, Turnbull F, Neal B et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-8.
207. Soto ME, van Kan GA, Nourhashemi F et al. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Reseau sur la Maladie d'Alzheimer Francais Cohort. J Am Geriatr Soc 2013; 61: 1482-8.
208. Krikov M, Thone-Reineke C, Muller S, Villringer A, Unger T. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens 2008; 26: 544-52.
209. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43: 1343-7.
210. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012; 308: 2108-17.
211. Johnell K, Religa D, Eriksdotter M. Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7, 000 patients. Dement Geriatr Cogn Disord 2013; 35: 239-48.
212. Handa T, Katare RG, Kakinuma Y et al. Anti-Alzheimer's drug, donepezil, markedly improves long-term survival after chronic heart failure in mice. J Cardiac Fail 2009; 15: 805-11.
213. Sato K, Urbano R, Yu C et al. The effect of donepezil treatment on cardiovascular mortality. Clin Pharmacol Ther 2010; 88: 335-8.
214. Kubo T, Sato T, Noguchi T et al. Influences of donepezil on cardiovascular system-possible therapeutic benefits for heart failure-donepezil cardiac test registry (DOCTER) study. J Cardiovasc Pharmacol 2012; 60: 310-4.
215. Nordstrom P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J 2013; 34: 2585-91.
216. Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp Gerontol 2005; 40: 165-71.
217. Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med 2009; 6: e1000157.
218. Okazaki Y, Zheng C, Li M, Sugimachi M. Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. J Physiol Sci 2010; 60: 67-74.
219. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004; 109: 120-4.
220. Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.
221. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-21.
222. Tanaka A, Koga S, Hiramatsu Y. Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes. Intern Med 2009; 48: 1219-23.
223. Tolppanen AM, Solomon A, Soininen H, Kivipelto M. Midlife vascular risk factors and Alzheimer's disease: evidence from epidemiological studies. J Alzheimers Dis 2012; 32: 531-40.
224. Kling MA, Trojanowski JQ, Wolk DA, Lee VM, Arnold SE. Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement 2013; 9: 76-92.
225. Haring B, Leng X, Robinson J et al. Cardiovascular disease and cognitive decline in postmenopausal women: results from the Women's Health Initiative Memory Study. J Am Heart Assoc 2013; 2: e000369.
226. Shah RC, Buchman AS, Wilson RS, Leurgans SE, Bennett DA. Hemoglobin level in older persons and incident Alzheimer disease: prospective cohort analysis. Neurology 2011; 77: 219-26.
227. Burashnikov A, Di Diego JM, Sicouri S et al. A temporal window of vulnerability for development of atrial fibrillation with advancing heart failure. Eur J Heart Fail 2014; 16: 271-80.
228. von Haehling S, Anker MS, Jankowska EA, Ponikowski P, Anker SD. Anemia in chronic heart failure: can we treat? What to treat? Heart Fail Rev 2012; 17: 203-10.
229. Palazzuoli A, Antonelli G, Nuti R. Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms. Heart Fail Rev 2011; 16: 603-7.
230. Santoro A. Anemia in renal insufficiency. Rev Clin Exp Hematol 2002; (Suppl 1): 12-20.
231. Sherman DG, Hart RG, Shi F. Heart-brain interactions: neurocardiology or cardioneurology comes of age. Mayo Clin Proc 1987; 62: 1158-60.
232. Natelson BH. Neurocardiology. An interdisciplinary area for the 80s. Arch Neurol 1985; 42: 178-84.
233. Rojas-Fernandez CH, Patel T, Lee L. An interdisciplinary memory clinic: a novel practice setting for pharmacists in primary care in Ontario, Canada. Ann Pharmacother 2014; 48: 785-95.
234. Gysan DB, Albus C, Riedel R et al. [CorBene: a new model for collaborative care of patients with congestive heart failure]. Herz 2012; 37: 56-8.
235. Leventhal ME, Denhaerynck K, Brunner-La Rocca HP et al. Swiss Interdisciplinary Management Programme for Heart Failure (SWIM-HF): a randomised controlled trial study of an outpatient inter-professional management programme for heart failure patients in Switzerland. Swiss Med Wkly 2011; 141: w13171.
236. van der Wall EE, van Gilst WH. Neurocardiology: close interaction between heart and brain. Neth Heart J 2013; 21: 51-2.
237. Luoto TM, Haikonen S, Haapasalo H et al. Large vessel cerebral atherosclerosis is not in direct association with neuropathological lesions of Alzheimer's disease. Eur Neurol 2009; 62: 93-8.
238. Zheng L, Vinters HV, Mack WJ, Zarow C, Ellis WG, Chui HC. Cerebral atherosclerosis is associated with cystic infarcts and microinfarcts but not Alzheimer pathologic changes. Stroke 2013; 44: 2835-41.
239. Forti P, Maioli F, Pisacane N, Rietti E, Montesi F, Ravaglia G. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment. Neurol Res 2006; 28: 625-9.
240. Peters R, Poulter R, Beckett N et al. Cardiovascular and biochemical risk factors for incident dementia in the Hypertension in the Very Elderly Trial. J Hypertens 2009; 27: 2055-62.
241. Rastas S, Pirttila T, Mattila K et al. Vascular risk factors and dementia in the general population aged >85 years: prospective population-based study. Neurobiol Aging 2010; 31: 1-7.